Why Vera Therapeutics Stock Rocked the Market on Tuesday
Key Points
The biotech received a significant boost from a new analyst note.
The prognosticator authoring it reiterated his strong buy recommendation on the stock.
- 10 stocks we like better than Otsuka ›
An analyst's very bullish new research note was the spark that lit a fire under the stock of Vera Therapeutics (NASDAQ: VERA) on Tuesday. That extremely positive investor reaction boosted the share price of the clinical-stage biotech by almost 13% on the day.
Price advantage?
The analyst in question was Ryan Deschner of Raymond James, who reiterated his strong buy recommendation on Vera stock. He also maintained his $73 per share price target on the healthcare company.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
According to reports, Deschner's update centered on its leading pipeline drug atacicept. This is a therapy being developed to treat the kidney disorder IgA nephropathy (IgAN), also known as Berger's disease.
The analyst noted that a potential competitor recently approved by the Food and Drug Administration (FDA), Otsuka Pharmaceutical's Voyxact, has been priced by its developer at $30,000 per once-ever-four-week treatment. That's around double what Deschner believes atacicept's cost will be.
Competitive right out of the gate
If Deschner's price assumption is correct, or even somewhat in the ballpark, Vera would have a clear advantage when and if its treatment does well in clinical trials and is ultimately approved by regulators.
As ever in the biotech world, of course, the "ifs" matter. So far, though, atacicept's development has generally progressed well, so I'd imagine it has at least a decent chance of reaching pharmacy shelves.
Should you invest $1,000 in Otsuka right now?
Before you buy stock in Otsuka, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Otsuka wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $588,530!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,102,885!*
Now, it’s worth noting Stock Advisor’s total average return is 1,012% — a market-crushing outperformance compared to 193% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of December 1, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
